Best Genomics Companies in Beijing, China
The 50 best Genomics companies in Beijing, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: EdiGene.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Beijing
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | EdiGene Developer of genome editing technology for the treatment of cancer and genetic disease | $165M | 63 mo ago | Series B | Dong Wei CEO | 140 | 103 patents Patents concentrated in chemistry & materials | — |
| 2 | Zhejiang Nuhui Health Technology Provider of early cancer screening and testing services | $152M | 72 mo ago | Public | Yiyou Chen Co-Founder | 1,041 | — | — |
| 3 | Bluepha Developer of synthetic biology and biomaterial | $133M | 41 mo ago | Series B | — | 120 | — | — |
| 4 | Xiantong Pharmaceutical Developer of radiopharmaceuticals for the diagnosis of tumors, neurodegenerative diseases and cardiovascular… | $100M | 37 mo ago | Series E | — | 400 | — | — |
| 5 | Murren Biotechnology Developer of microbial separation and cultivation technologies 40Moat top 22%Funding top 38%Market top 48%Talent bottom 49% All 5 signals ▾Moattop 22% Fundingtop 38% Markettop 48% Talentbottom 49% Globalbottom 29% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $50.6M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $51M | 25 mo ago | Series C | Jiang Xianzhi Founder & CEO | 50 | — | — |
| 6 | Hugo Biotech Developer of cloud-based pathogenic microorganism data analysis system | $34M | 70 mo ago | Series A | Han Xia Founder & CEO | — | — | — |
| 7 | Yikon Genomics Provider of NIPT and liquid biopsy tests using next-generation sequencing | $31M | 81 mo ago | Series C | — | 5,000 | 21 patents Patents concentrated in chemistry & materials | — |
| 8 | Sino Biological Provider of reagents,and kits for clinical research | $29M | 109 mo ago | Series A | Liangzhi Xie President And Ceo | 913 | — | — |
| 9 | Beijing Rubber Xin Biological Technology Developer of tumor genetic testing reagents and instruments | $29M | 43 mo ago | Series B | Cao Shanbai CEO | — | — | — |
| 10 | Beijing Zhongyin Technology Digital clinical genetic diagnosis tool for providers 42Funding top 41%Talent bottom 45%Global bottom 29% All 3 signals ▾Fundingtop 41% Talentbottom 45% Globalbottom 29% Funding: Raised $26.5M · 3 rounds over 5 yrs (0.6/yr) Talent: 1 named leader on record rank vs industry peers · Fliar Intelligence Index 42/100 | $26M | 34 mo ago | Series A | Zhong Xiancheng CEO | — | — | — |
| 11 | Safford Decoding Provider of genetic analysis and precision medicine services | $26M | 62 mo ago | Series B | Wei L Founder | 160 | — | — |
| 12 | Mega Genomics Provider of whole-exome sequencing services | $25M | 117 mo ago | Public | — | 267 | — | — |
| 13 | Beijing Xinyi Biotechnology Manufacturer of micro-droplet digital PCR and in vitro diagnostic reagents | $23M | 29 mo ago | Series B | Wenjun Yang Co-Founder | — | — | — |
| 14 | Pregene Provider of reagents and kits for molecular biology research | $21M | 68 mo ago | Series B | — | 102 | — | — |
| 15 | Genebox Developer of genetic test kit for health and fitness | $20M | 68 mo ago | Series A | Daniel Li Founder & CEO | 60 | — | — |
| 16 | Berry Genomics Provider of genetic testing products and tests | $16M | 136 mo ago | Public | — | 1,438 | 92 patents Non‑invasive prenatal testing and hereditary mutation detection using targeted sequencing kits. | — |
| 17 | Sino Valley Biotechnology Provider of genetic testing for canine and other pet animals | $16M | 57 mo ago | Series B | — | 70 | — | — |
| 18 | Beijing Youxun Medical Laboratory Provider of tests for detecting non-invasive single gene disorders, prenatal testing and tumor detection | $15M | 50 mo ago | Series B | Ye Zhou CEO | — | — | — |
| 19 | Bioyong Provider of clinical mass spectrometry systems | $15M | 110 mo ago | Series B | Ma Qingwei Founder & CEO | 140 | 3 patents Disease biomarker detection via mass‑spectrometry proteomics for clinical diagnostics | — |
| 20 | Jiabao Next-generation sequencing integration services for assisted pregnancy | $14M | 71 mo ago | Series B | Feng Tao Co-Founder & CEO | — | 4 patents Air purification systems and related filtration technologies | — |
| 21 | Zhinuvis Provider of AI based tools for tumor gene and pathology analysis | $9M | 80 mo ago | Series B | Ling Shaoping Founder & CEO | — | — | — |
| 22 | XTAO Solutions for data analysis, dash-boarding, and reporting | $7M | 73 mo ago | Seed | Javen Wu Founder | — | — | — |
| 23 | Quantibio Provider of gene mapping services of the human gut microbiome | $5M | 103 mo ago | Series A | Bowen Zhao Founder & CEO | — | — | — |
| 24 | Genessential Provider of genetic tests for health and nutrition | $1M | 91 mo ago | Seed | Jack Chen CEO | — | — | — |
Top 12 Genomics companies in Beijing
#1
Series C · Beijing, Beijing · founded 2015 · 50 employees$50.6Mraised▾
Developer of microbial separation and cultivation technologies. It has developed Eco-screening TM technology, fungal high-density solid fermentation technology foroxygen, H2O, pH value, carbon, & nitrogen source, and microfilm coating technology on the surface of seeds to stop the damage of microorganisms. It has applications in biological agriculture, human microbiome research biomedicine, and gene discovery.
- Jul 2024Series C$41.3M
- Feb 2020Series B—
- Jun 2018Seed$9.3M
#2
Series B · Haidian, Beijing · founded 2015$23.2Mraised▾
Beijing Xinyi Biotechnology is manufacturing micro-droplet digital PCR and in vitro diagnostic reagents. Products include drop maker sample preparation, chip reader, PCR universal amplification reagent, genetic testing kit (for scientific research only), micro-droplet detection oil, nucleic acid extraction reagent (magnetic beads method), etc.
- Feb 2024Series B—
- Jan 2021Series B$23.2M
- Sep 2018Seed—
#3
Series B · Beijing, Beijing · founded 2016 · 120 employees$133Mraised▾
Developer of synthetic biology and biomaterial. The company has microbial manufacturing technology that helps in developing bio-based products for a broad range of industries, including consumer goods, healthcare, specialty chemicals, agriculture, electronics, and more
- Feb 2023Conventional Debt$73.3M
- Feb 2023Series B$58.6M
- Jan 2022Series B—
- Aug 2021Series B$66.4M
#4
Series E · Beijing, Beijing · founded 2004 · 400 employees$99.5Mraised▾
Developer of radiopharmaceuticals for the diagnosis of tumors, neurodegenerative diseases, and cardiovascular diseases. The company has developed nuclear medicine for the treatment. It has also developed several diagnostic agents.
- Jul 2023Series E—
- Oct 2021Series D$50M
- Feb 2021Series D$49.5M
#5
Series A · Haidian, Beijing · founded 2015$26.5Mraised▾
Developer of clinical genetic diagnosis, fertility prevention and gene therapy drug for hereditary eye diseases. The company specializes in developing ophthalmic gene therapy drugs backed by accurate gene diagnosis, providing reliable ophthalmic gene pharmaceuticals for the public.
#6
Series B · Changping District, Beijing · founded 2015 · 140 employees$165.5Mraised▾
Developer of genome editing technology for the treatment of cancer and genetic disease. The company has developed LEAPER technology, which is an in vivo oligonucleotide-based RNA single-base editing technology used for the treatment of Hurler syndrome. The company's in vitro therapy includes ET-01 for β-thalassemia major and the allogeneic CAR-T ET-02 for cancer.
- Apr 2021Series B$61.5M
- Oct 2020Series B$67M
- Sep 2019Series A$11.5M
- Feb 2019Series A$10.5M
#7
Series B · Haidian, Beijing · founded 2017$28.7Mraised▾
Developer of tumor genetic testing reagents and instruments. It has developed AcornSTAS for solid tumor mutations, AcornHMAS for hematological tumor mutations, AcornSTDB which is a solid tumor gene knowledge database and others.
- Dec 2022Series B$28.7M
- Apr 2020Series A—
#8
Public · Beijing, Beijing · founded 2013 · 1041 employees$151.8Mraised▾
Provider of early cancer screening and testing services. The company has developed a fecal gene analysis (FIT-DNA) technology for colorectal cancer screening. The company also has a product for gastric cancer detection through their Helicobacter pylori toxicity factor detection technology. The company leverages its expertise in genetic testing, molecular diagnostics, and large data platforms and software in developing early detection tests for cancer.
- Jul 2020Series E$30M
- Apr 2020Series D$20M
- May 2019Series C$66M
- Aug 2017Series B$20M
#9
Series B · Haidian, Beijing · founded 2014$14.9Mraised▾
Provider of tests for detecting non-invasive single gene disorders, prenatal testing, and tumor detection. The services include hereditary tumor susceptibility gene screening, tumor personalized treatment gene detection, circulating tumor DNA (ct DNA) detection, circulating tumor cells (CTC ) assessment, and monitoring.
- May 2022Series B—
- Jul 2017Series A—
#10
Series B · Beijing, Beijing · founded 2015 · 160 employees$25.6Mraised▾
Provider of genetic analysis and precision medicine services. The tests reports enable the clinicians to offer treatment plans as per the individual's genetic profile. The company is developing a genetic analysis platform for gene-related data. Clinical needs provide clinicians with an accurate basis for diagnosis and treatment, thereby enhancing their clinical benefit. The company exon gene sequencing data analysis and interpretation technology to provide treatment for rare diseases, cancer, diabetes, and cardiovascular diseases.
- May 2021Series B$15.6M
- Jul 2020Series A—
- May 2018Series A—
- Feb 2016Seed$10M
#11
Series B · Changping District, Beijing · founded 2012 · 70 employees$15.6Mraised▾
Provider of genetic testing for canine and other pet animals. It offers kits for gene detection along with gene editing, cell therapy for animal cloning, and offers a database for animal diversity and genetic information.
- Nov 2021Series B$15.6M
- Jun 2020Series B—
#12
Series A · Beijing, Beijing · founded 2017$33.5Mraised▾
HUGO BIOTECH is a developer of cloud-based pathogenic microorganism data analysis system PACE. The device is used for image capture, visualization, and biological significance analysis. The Illumina Genetic Analyzer Pipeline software is used to perform preliminary analysis on the data to obtain conversion from image capture to intensity signal value, and then calculate to base sequence. It helps to determine the DNA sequence of pathogenic microorganisms in clinical samples like cerebrospinal fluid, blood, alveolar lavage fluid, sterile body fluids, tissues, and other sources.
- Sep 2020Series A$32.1M
- Jun 2020Seed$1.4M
- Feb 2020Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Beijing is moving
A read on the academic research around Bioinformatics in Beijing — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 762 papers.
- Beijing University of Chinese Medicine82
- Beijing Proteome Research Center35
- Beijing Tian Tan Hospital31
- Beijing University of Chemical Technology28
- Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine28
- Gene2→24
- Genome3→17
- Identification (biology)2→14
- Metagenomics1→9
- Phenotype1→6
- Mechanism (biology)1→16
- Identification (biology)1→9
- microRNA1→8
- Function (biology)1→8
- Microvesicles1→4
- Disease13
- Immune system12
- Cancer8
- Translational research8
- MEDLINE7
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.